Related Experiment Video
Updated: Jun 22, 2026
07:01
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
Targeting CD133 antigen in cancer
Gabriella Ferrandina1, Marco Petrillo, Giuseppina Bonanno
1Catholic University, Gynecologic Oncology Unit, L.go A. Gemelli 1, 86100 Campobasso, Italy. gabriella.ferrandina@libero.it
Expert Opinion on Therapeutic Targets
|June 18, 2009
Summary
CD133 is a marker for cancer stem cells (CSCs) linked to poor prognosis and treatment resistance. Targeting CD133+ CSCs offers new therapeutic strategies for cancer cure.
Area of Science:
- Oncology
- Cancer Stem Cell Biology
- Molecular Oncology
Background:
- CD133 is recognized as a marker for cancer stem cells (CSCs) with self-renewal capabilities.
- CSCs are implicated in tumor initiation, progression, and resistance to therapies.
- Eradicating CSCs is considered crucial for achieving a definitive cancer cure.
Purpose of the Study:
- To review current evidence on CD133's role as a CSC marker in human cancers.
- To explore therapeutic strategies targeting CD133 and its associated pathways.
Main Methods:
- Literature search of Medline database.
- Keywords: 'CD133 and cancer targeting', 'CD133 and chemo resistance', 'CD133 and molecular pathways'.
- Inclusion criteria: Published full articles in English.
Main Results:
- CD133 expression is confirmed as a marker for CSCs in various human neoplasms.
- CD133+ CSCs are associated with unfavorable patient prognosis.
- Emerging therapeutic strategies focus on targeting molecular pathways essential for CD133+ CSC survival.
Conclusions:
- CD133 serves as a validated marker for CSCs across multiple cancer types.
- Its presence often correlates with a poorer clinical outcome.
- Targeting CD133+ CSCs represents a promising avenue for novel cancer treatments.
